Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

Table 2 Overall survival data

Outcome (n, %)	Survival (months)	p-value	HR (95% CI)	p-value
≥30% PSA response at 4 weeks (97)
Yes (38, 39.2)	40.0 (23.9–55.0)	0.014	0.54 (0.33–0.89)	0.015
No (59, 60.8)	19.7 (16.0–25.1)	0.014	0.54 (0.33–0.89)	0.015
≥50% PSA response at 4 weeks (97)
Yes (32, 33.0)	41.1 (23.2-NE)	0.007	0.49 (0.28–0.83)	0.006
No (65, 67.0)	19.9 (16.0–26.1)	0.007	0.49 (0.28–0.83)	0.006
≥30% PSA response at 8 weeks (95)
Yes (46, 48.4)	40.0 (25.1–48.4)	0.004	0.51 (0.32–0.82)	0.005
No (49, 51.6)	18.7 (16.0–23.9)	0.004	0.51 (0.32–0.82)	0.005
≥50% PSA response at 8 weeks (95)
Yes (35, 36.8)	37.4 (23.9–46.0)	0.058	0.62 (0.38–1.02)	0.054
No (60, 63.2)	20.3 (17.8–26.1)	0.058	0.62 (0.38–1.02)	0.054
≥30% PSA response at 12 weeks (93)
Yes (51, 54.8)	35.2 (24.0–45.7)	0.017	0.56 (0.35–0.91)	0.019
No (42, 45.2)	18.6 (13.4–23.9)	0.017	0.56 (0.35–0.91)	0.019
≥50% PSA response at 12 weeks (93)
Yes (40, 43.0)	40.0 (26.1–55.0)	0.002	0.47 (0.29–0.77)	0.002
No (54, 57.0)	19.6 (15.0–23.9)	0.002	0.47 (0.29–0.77)	0.002

Data from Kaplan Meyer and univariate cox regression analyses for a PSA response ≥30% and ≥ 50% at four, eight, and twelve weeks. Median survival is presented in months (95% CI). NE = not evaluable. P-values in bold text are statistically significant (p ≤ 0.05)

ISSN: 1471-2407